Total Payments
$2.9M
2024 Payments
$81,859
Companies
9
Transactions
144
Medicare Patients
864
Medicare Billing
$412,969
Payment Breakdown by Category
Other$2.7M (94.2%)
Consulting$152,090 (5.2%)
Research$15,008 (0.5%)
Travel$1,148 (0.0%)
Food & Beverage$510.38 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.7M | 6 | 94.2% |
| Consulting Fee | $152,090 | 103 | 5.2% |
| Unspecified | $15,008 | 25 | 0.5% |
| Travel and Lodging | $1,148 | 4 | 0.0% |
| Food and Beverage | $510.38 | 6 | 0.0% |
Payments by Type
General
$2.9M
119 transactions
Research
$15,008
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Veru Inc. | $2.7M | 9 | $0 (2024) |
| Merck Sharp & Dohme LLC | $116,310 | 81 | $0 (2024) |
| Seagen Inc. | $16,905 | 10 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $12,508 | 23 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $12,444 | 9 | $0 (2022) |
| PFIZER INC. | $6,144 | 8 | $0 (2017) |
| GENZYME CORPORATION | $2,500 | 2 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,485 | 1 | $0 (2017) |
| EMD Serono, Inc. | $13.59 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $81,859 | 18 | Veru Inc. ($49,799) |
| 2023 | $82,519 | 17 | Veru Inc. ($59,084) |
| 2022 | $2.7M | 21 | Veru Inc. ($2.6M) |
| 2021 | $31,780 | 22 | Merck Sharp & Dohme Corporation ($22,750) |
| 2020 | $19,274 | 18 | Merck Sharp & Dohme Corporation ($14,350) |
| 2019 | $8,570 | 9 | Merck Sharp & Dohme Corporation ($3,613) |
| 2018 | $13,093 | 19 | Merck Sharp & Dohme Corporation ($6,625) |
| 2017 | $13,003 | 20 | PFIZER INC. ($6,144) |
All Payment Transactions
144 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Veru Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Dividend, profit or other return on investment | $28,957.50 | General |
| 09/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | Veru Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Dividend, profit or other return on investment | $20,490.00 | General |
| 07/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 07/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 07/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2024 | Veru Inc. | — | Food and Beverage | In-kind items and services | $208.61 | General |
| 06/05/2024 | Veru Inc. | — | Food and Beverage | In-kind items and services | $143.09 | General |
| 04/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 01/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: ONCOLOGY | ||||||
| 01/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 01/03/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2023 | Seagen Inc. | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| 10/25/2023 | Seagen Inc. | — | Consulting Fee | Cash or cash equivalent | $305.00 | General |
| 10/11/2023 | Seagen Inc. | PADCEV (Biological) | Consulting Fee | Cash or cash equivalent | $2,360.00 | General |
| Category: Oncology | ||||||
| 10/02/2023 | Veru Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Dividend, profit or other return on investment | $42,112.00 | General |
| 08/21/2023 | Veru Inc. | ENTADFI (Drug) | Food and Beverage | In-kind items and services | $95.84 | General |
| Category: UROLOGY | ||||||
| 08/07/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 3 RCT in mCRPC comparing 75 mg/m2 docetaxel with prednisone with cabazitaxel 25 mg/m2 with prednisone and cabazitaxel 20 mg/m2 with prednisone. | GENZYME CORPORATION | $2,500 | 2 |
| Phase 3 RCT in 1222 patients with mCRPC previously treated with docetaxel comparing cabaiztaxel 20 mg/m2 with prednisone versus cabazitaxel 25 mg/m2 with prednisone (PROSELICA),Randomized, Open label, | SANOFI-AVENTIS U.S. LLC | $2,084 | 3 |
| Phase 3 RCT in 1222 patients with mCRPC previously treated with docetaxel comparing cabaiztaxel 20 mg/m2 with prednisone versus cabazitaxel 25 mg/m2 with prednisone | SANOFI-AVENTIS U.S. LLC | $1,686 | 3 |
| Cabazitaxel at 20 mg Compared to 25 mg With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (PROSELICA) | SANOFI-AVENTIS U.S. LLC | $1,297 | 1 |
| Phase 3 RCT in 1222 patients with mCRPC previously treated with docetaxel comparing cabaiztaxel | SANOFI-AVENTIS U.S. LLC | $982.66 | 2 |
| PROSELICA (Randomized, Open-Label Multicenter Study Comparing Cabazitaxel at 20 mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration-Resistant | SANOFI-AVENTIS U.S. LLC | $942.52 | 3 |
| A Randomized Non-Comparative Phase II Trial of Early Switch from Docetaxel to Cabazitaxel or Vice Versa, with Integrated Biomarker Analysis, in Men with Chemotherapy-Na?ve Metastatic Castration-Resis | SANOFI-AVENTIS U.S. LLC | $885.88 | 2 |
| Phase 3 RCT in 1222 patients with mCRPC previously treated with docetaxel comparing cabaiztaxel 20 mg/m2 with prednisone versus cabazitaxel 25 mg/m2 with prednisone (PROSELICA) | SANOFI-AVENTIS U.S. LLC | $872.67 | 1 |
| Cabazitaxel at 20 mg/m? Compared to 25 mg/m? With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer, Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With | SANOFI-AVENTIS U.S. LLC | $831.85 | 1 |
| Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resist | SANOFI-AVENTIS U.S. LLC | $629.91 | 1 |
| Association of Grade 3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel | SANOFI-AVENTIS U.S. LLC | $591.64 | 1 |
| Post hoc responder analysis of health-related quality of life (HRQL) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the Phase III PROSELICA and FIRST | SANOFI-AVENTIS U.S. LLC | $591.64 | 1 |
| Association of grade 3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel | SANOFI-AVENTIS U.S. LLC | $570.55 | 1 |
| Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate C | SANOFI-AVENTIS U.S. LLC | $296.57 | 1 |
| Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated on the TAXYNERGY study | SANOFI-AVENTIS U.S. LLC | $244.96 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 9 | 415 | 1,897 | $356,241 | $204,148 |
| 2020 | 8 | 449 | 1,946 | $454,032 | $208,821 |
Total Patients
864
Total Services
3,843
Medicare Billing
$412,969
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3315 | Injection, triptorelin pamoate, 3.75 mg | Office | 2021 | 77 | 525 | $181,158 | $140,565 | 77.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 52 | 255 | $81,564 | $29,501 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 108 | 195 | $46,478 | $19,621 | 42.2% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 92 | 215 | $20,743 | $6,221 | 30.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 16 | 32 | $12,444 | $4,093 | 32.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 33 | 43 | $6,810 | $3,220 | 47.3% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 13 | 58 | $3,631 | $875.44 | 24.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 11 | 254 | $2,007 | $28.89 | 1.4% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2021 | 13 | 320 | $1,405 | $23.26 | 1.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2020 | 84 | 495 | $172,203 | $85,514 | 49.7% |
| J3315 | Injection, triptorelin pamoate, 3.75 mg | Office | 2020 | 66 | 312 | $150,846 | $78,807 | 52.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 103 | 165 | $39,328 | $14,767 | 37.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 59 | 117 | $37,656 | $14,455 | 38.4% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 12 | 58 | $22,555 | $7,328 | 32.5% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2020 | 103 | 223 | $21,515 | $6,053 | 28.1% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 11 | 128 | $8,013 | $1,864 | 23.3% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2020 | 11 | 448 | $1,916 | $32.35 | 1.7% |
About Dr. Mario Eisenberger, M.D
Dr. Mario Eisenberger, M.D is a Medical Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699722850.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mario Eisenberger, M.D has received a total of $2.9M in payments from pharmaceutical and medical device companies, with $81,859 received in 2024. These payments were reported across 144 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.7M).
As a Medicare-enrolled provider, Eisenberger has provided services to 864 Medicare beneficiaries, totaling 3,843 services with total Medicare billing of $412,969. Data is available for 2 years (2020–2021), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Baltimore, MD
- Active Since 05/31/2006
- Last Updated 02/06/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1699722850
Products in Payments
- KEYTRUDA (Biological) $91,805
- JEVTANA (Drug) $15,008
- PADCEV (Biological) $14,160
- LENVIMA (Drug) $12,000
- WELIREG (Drug) $8,845
- OPDIVO (Biological) $7,800
- XTANDI (Drug) $2,134
- Xofigo (Drug) $1,485
- ENTADFI (Drug) $95.84
- Bavencio (Drug) $13.59
- ELIQUIS (Drug) $4.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Baltimore
Dr. Tanguy Seiwert, M.d, M.D
Medical Oncology — Payments: $622,422
Medical Oncology $622,422
Carole Miller, Md, MD
Medical Oncology — Payments: $587,841
Medical Oncology $587,841
Bruce Smith, M.d, M.D
Medical Oncology — Payments: $406,689
Medical Oncology $406,689
Carol Huff, M.d, M.D
Medical Oncology — Payments: $384,580
Medical Oncology $384,580
Leisha Emens
Medical Oncology — Payments: $252,501
Medical Oncology $252,501
Enser Cole, Md, MD
Medical Oncology — Payments: $220,743
Medical Oncology $220,743